Home

WESEEYOU®

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis, also known as primary biliary cholangitis (PBC), and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Thursday, February 4, 2016

Intercept to Present at Upcoming Investor Conferences
See the press release >

You are now being redirected to Intercept’s job application site, hosted by Pereless Systems.